Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI
Clinical trial NCT06441045 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06441045
- Sponsor
- Fujian Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-01
- Primary completion
- 2028-04-01
- Enrollment
- 112
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.